Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis
Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis
复制标题
DOI：
10.1002/ijc.10444
复制
发表时间：
2002-07-01
影响因子：
6.4
通讯作者：
Ekbom, A
中科院分区：
文献类型：
--
作者：
Knight, A;Askling, J;Ekbom, A
韦格纳肉芽肿病是一种不明原因的坏死性肉芽肿性血管炎，未经治疗，在发病第一年内死亡率很高。在治疗中引入皮质类固醇和环磷酰胺大大提高了生存率，但过去的研究表明癌症风险增加，包括膀胱癌的风险增加。尚未报道对韦格纳肉芽肿病的一般癌症发生率进行大规模评估。我们研究的目的是评估韦格纳肉芽肿病患者癌症的一般发病率，并将其与膀胱癌的风险联系起来。我们在瑞典住院患者登记册中确定了一个由 1,065 名韦格纳肉芽肿患者组成的基于人群的队列。通过与瑞典癌症登记处的联系，我们对癌症发生队列进行了长达 26 年的跟踪。观察到的癌症数量与预期癌症数量之间的标准化发病率比（SIR）被用作相对风险的衡量标准。该队列中患癌症的总体风险增加了两倍。膀胱癌（SIR = 4.8；95% CI 2.6-8.1）、鳞状细胞皮肤癌（SIR = 7.3；95% CI 4.4-12）、白血病（SIR = 5.7；95% CI 2.3-12）和恶性淋巴瘤（SIR = 4.2；95% CI）的增加最为明显。 4.2-8.3）。结果证实了先前关于膀胱癌风险增加的迹象，但也表明其他部位患癌症的风险增加。 (C) 2002 Wiley-Liss, Inc.
Wegener's granulomatosis is necrotizing granulomatous vasculitis of unknown origin, which untreated has a high mortality within the first year of onset. The introduction of corticosteroids and cyclophosphamide in the treatment has considerably improved survival rates, but past studies have indicated an increased cancer risk, including an increased risk for urinary bladder cancer. No large assessment of the general cancer occurrence in Wegener's granulomatosis has been reported, The aim of our study was to assess the general incidence of cancer in patients with Wegener's granulomatosis and to put this in relation to the risk for bladder cancer. We identified a population-based cohort of 1,065 patients with Wegener's granulomatosis in the Swedish Inpatient Register. Through linkage with the Swedish Cancer Register, we followed the cohort for cancer occurrence for up to 26 years. Standardized incidence ratios (SIR) between observed and expected numbers of cancers were used as a measure of relative risk. There was a 2-fold overall increased risk for cancer in the cohort. The increase was most pronounced for bladder cancer (SIR = 4.8; 95% CI 2.6-8.1), squamous cell skin cancer (SIR = 7.3; 95% CI 4.4-12), leukemias (SIR = 5.7; 95% CI 2.3-12) and for malignant lymphomas (SIR = 4.2; 95% CI 4.2-8.3). The results confirm previous indications of an increased risk for cancer of the urinary bladder but also points to increased risks for cancer at other sites. (C) 2002 Wiley-Liss, Inc.